Date：27 July (Wednesday)
Time: 12:20 – 13:50 (GMT+8)
Country President and General Manager
Novartis (Taiwan) Co., Ltd.
Jorge Wagner is a passionate and distinguished commercial leader with over 25 years of multinational experience in the pharmaceutical industry. He has a wide spectrum of capabilities and professional experiences in marketing and general management across different geographic areas and cultures, including Indonesia, Germany, Argentina, Ecuador, and Taiwan, demonstrating leadership and impact on local and regional level. He establishes a strong record of driving commercial excellence and leading cultural transformation while dedicating policy shaping and governmental affairs.
Jorge is appointed as Country President at Novartis Taiwan since November 2020, and relocated from his previous role as Country President of Novartis in Jakarta, Indonesia. He is currently a Standing Director of International Research-Based Pharmaceutical Manufacturers Association (IRPMA), Taiwan, a co-chair of pharmaceutical committee in the European Chamber of Commerce Taiwan (ECCT) from June 2021, and also serves as a co-chair of public health committee in the American Chamber of Commerce in Taiwan (AmCham) since August 2021. During his time in Indonesia, he was the Chairman of the Indonesian International Pharmaceutical Companies Association (IPMG) from 2017 to 2020.
Prior to Novartis, Jorge worked for more than 20 years at Boehringer Ingelheim, and had various roles worldwide. He received his Industrial Engineer degree from the Instituto Tecnologico Buenos Aires and obtained his post graduated in Marketing from the University of San Andres, Buenos Aires, as well as studied at London Business School.
Taiwan has world leading ICT industry, outstanding healthcare professionals and high quality healthcare system, with comprehensive database such as the NHI data, which provide a very strong infrastructure for digital health development on many aspects.
As Novartis committed to be the leading medicines company powered by data science and digital technologies, we are actively collaborating with Taiwanese tech companies, including the renowned giant ACER, to pursue various digital solutions for better patient outcome. Following the success of the first AI-based diagnostic software for diabetic retinopathy, the two companies are now working together again on next project, an AI-based disease activity prediction tool which can assist ophthalmologists to develop a precise treatment plan with more efficient follow-up schedule, enhanced compliance and potentially better outcomes.
But Novartis is not the only big-pharma heavily invested here. Together with H2S, a Taiwanese tech company, Sanofi’s Diabetes Digital Solution has shown significant steps to improve Taiwan diabetes management ecosystem and treatment outcome, with continuous investment on clinical trials and RWE generation programs. AstraZeneca, by working with Taiwan tech start-up, is also scaling up the implementation of integrated COPD diagnosis platform in primary care settings. And there are many more examples from IRPMA member companies. We look forward to partnering with local tech ecosystem on more collaborations, and fostering a supportive & attractive environment for cross-industry investment, making Taiwan a cradle for digital health in the APAC region. Suggestions from member companies will be shared in the talk.